[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345720-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345720-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comprehensive-pan-cancer-analysis-and-experimental-verification-of-egln-family-potential-biomarkers-in-cervical-cancer","Comprehensive Pan-cancer Analysis and Experimental Verification of EGLN Family - Potential Biomarkers in Cervical Cancer","","Hypoxia drives malignant tumor formation largely through hypoxia-inducible factors, yet the cancer relevance and prognostic significance of the EGLN gene family (EGLN1, EGLN2, EGLN3) remain unclear. This study integrates public databases and bioinformatics analyses using expression, mutation, stemness, and clinical data, then applies enrichment/pathway methods and ssGSEA. Colocalization, eQTL/GWAS integration, and immunohistochemistry validate EGLN expression in cervical cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-pan-cancer-analysis-and-experimental-verification-of-egln-family-potential-biomarkers-in-cervical-cancer/345720/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-pan-cancer-analysis-and-experimental-verification-of-egln-family-potential-biomarkers-in-cervical-cancer/345720.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus regarding EGLN in this study?","Question",{"text":63,"@type":64},"The study investigates how the EGLN gene family (EGLN1, EGLN2, EGLN3) is involved across cancer types and whether it has prognostic and biomarker potential in cervical cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were EGLN genes analyzed across cancers?",{"text":68,"@type":64},"Public databases (TCGA, GTEx, TARGET, GEO) and bioinformatics tools were used to integrate gene expression, mutation data, stemness scores, and clinical information, followed by enrichment/pathway analyses and ssGSEA.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental evidence supports the findings for cervical cancer?",{"text":72,"@type":64},"Colocalization analysis using eQTL and GWAS data was performed, and immunohistochemistry was used to validate EGLN expression in cervical cancer tissues.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345720,1790500216,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","176  \nSend Orders for Reprints [to reprints@benthamscience.net](to reprints@benthamscience.net)  \nCurrent Cancer Drug Targets, 2026, 26, 176-197  \nRESEARCH ARTICLE  \nComprehensive Pan-cancer Analysis and Experimental Verification of EGLN Family: Potential Biomarkers in Cervical Cancer  \nDongli Zhang1,2,\\#, Ruifang Fu2,\\#, Guixia Sun2, Junfang Yan2 and Xiaofeng Yang1,*  \n1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi 710061, P.R. China; 2Department of Obstetrics and Gynecology, Huaihe Hospital of Henan University, Henan, Kaifeng 475000, P.R. China  \n© 2026 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 [https://creativecommons.org/licenses/by/4.0/legalcode](https://creativecommons.org/licenses/by/4.0/legalcode)  \nCurrent Cancer Drug Targets  \nAbstract: Background: Hypoxia plays a crucial role in malignant tumor formation, primarily mediated by hypoxia-inducible factors (HIFs) . Despite extensive research, the complexities and prognostic implications of the EGLN gene family (EGLN1, EGLN2, EGLN3) in cancers remain unclear.  \nMethods: Utilizing public databases (TCGA, GTEx, TARGET, GEO) and bioinformatics tools, a comprehensive analysis of EGLN genes across various cancer types was conducted. Gene expression, mutation data, stemness scores, and clinical information were integrated to evaluate the mutation landscape, expression levels, and prognostic values of EGLNs. Enrichment and pathway analyses explored EGLN-associated biological processes and functional networks. ssGSEA constructed EGLN scores for prognostic evaluation. Colocalization analysis combined eQTL and GWAS data to investigate genetic variations in cervical cancer. Immunohistochemistry validated EGLN expression in cervical cancer tissues.  \nResults: EGLN genes showed differential expression across cancer types. EGLN1 overexpression was associated with worse survival in cervical squamous cell carcinoma (CESC), pancreatic adenocarcinoma (PAAD), and neuroblastoma (NB), while EGLN3 was linked to poor survival in CESC, lung adenocarcinoma (LUAD), and kidney cancers. EGLNs also demonstrated varied roles in modulating tumor immune activity and heterogeneity.  \nConclusion: This study provides new insights into EGLN biology and identifies EGLN1 as a potential biomarker for cervical cancer.  \nKeywords: Hypoxia, pan-cancer, EGLN family, bioinformatics analysis, biomarker discovery.  \n1. INTRODUCTION  \nCervical cancer is a heavy disease burden among women globally, with varying incidence rates across regions [1, 2] . The incidence of cervical cancer varies across regions, with higher rates in developing countries due to limited access to screening and vaccination programs [3] . Based on the Global Cancer Statistics 2020, cervical cancer ranks as the fourth most prevalent cancer affecting women worldwide [4] . Cervical cancer treatment typically involves surgical removal, radiation therapy, chemotherapy, emerging targeted therapy, and immunotherapy based on the cancer stage [5] . However, cervical cancer management continues to present significant  \n*Address correspondence to this author at the Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an,  \nShanxi 710061, P.R. China; [E-mail: yxf73@163.com](E-mail: yxf73@163.com)  \n[\\#](#These authors contributed equally to this work)[These authors contributed equally to this work](#These authors contributed equally to this work)  \n1873-5576/26  \nchallenges, including the restricted availability of screening and vaccination initiatives, cultural obstacles, and disparities in healthcare access [6, 7] . Timely detection and intervention with Pap tests are crucial to achieving favorable prognoses based on clinical guidelines [8-10] . Nevertheless, the current repertoire of biomarkers for diagnostic and prognostic purposes in clinical settings is limited, un","cbCaitUjZt1GStk4","https://ap.wps.com/l/cbCaitUjZt1GStk4","pdf",13980175,22,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the main focus regarding EGLN in this study?\",\"answer\":\"The study investigates how the EGLN gene family (EGLN1, EGLN2, EGLN3) is involved across cancer types and whether it has prognostic and biomarker potential in cervical cancer.\"},{\"question\":\"How were EGLN genes analyzed across cancers?\",\"answer\":\"Public databases (TCGA, GTEx, TARGET, GEO) and bioinformatics tools were used to integrate gene expression, mutation data, stemness scores, and clinical information, followed by enrichment/pathway analyses and ssGSEA.\"},{\"question\":\"What experimental evidence supports the findings for cervical cancer?\",\"answer\":\"Colocalization analysis using eQTL and GWAS data was performed, and immunohistochemistry was used to validate EGLN expression in cervical cancer tissues.\"}]","Comprehensive Pan-cancer Analysis and Experimental Verification of EGLN Family - Potential Biomarkers in Cervical Cancer | PDF",1790058693,55,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2a38ffed4f06c76a4e11d4045af5732.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00078e9e0a6b9b81f806d744f3810e59.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9bec9d0140e75e1a83aaf87add79416a.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a21fa067c407668997f2a3fabe1f4379.webp",980,1268]